Medline (NASDAQ:MDLN) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says

Medline (NASDAQ:MDLN) had its price objective raised by Wells Fargo & Company from $42.00 to $47.00 in a research report issued to clients and investors on Friday,Benzinga reports. The firm currently has an “equal weight” rating on the stock. Wells Fargo & Company‘s target price indicates a potential downside of 1.07% from the stock’s current price.

A number of other analysts have also recently commented on the stock. Jefferies Financial Group began coverage on shares of Medline in a research report on Monday, January 12th. They issued a “buy” rating and a $50.00 price objective for the company. BTIG Research restated a “buy” rating and issued a $55.00 price target (up from $50.00) on shares of Medline in a report on Wednesday, January 21st. The Goldman Sachs Group initiated coverage on Medline in a report on Monday, January 12th. They set a “buy” rating and a $49.00 price objective on the stock. Piper Sandler initiated coverage on Medline in a research note on Monday, January 12th. They set an “overweight” rating and a $50.00 target price for the company. Finally, Bank of America assumed coverage on shares of Medline in a research note on Monday, January 12th. They issued a “buy” rating and a $50.00 price target on the stock. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $50.35.

Medline Price Performance

Shares of MDLN stock opened at $47.51 on Friday. The company has a 50-day moving average of $44.52. Medline has a one year low of $34.89 and a one year high of $50.88.

Medline (NASDAQ:MDLN) last issued its quarterly earnings data on Wednesday, February 25th. The company reported ($0.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.24 by ($0.25). The company had revenue of $7.79 billion for the quarter, compared to analysts’ expectations of $7.52 billion. The firm’s revenue was up 14.8% on a year-over-year basis.

Insider Buying and Selling at Medline

In other Medline news, Director Charles N. Mills bought 2,579,310 shares of Medline stock in a transaction that occurred on Thursday, December 18th. The stock was acquired at an average price of $29.00 per share, for a total transaction of $74,799,990.00. Following the completion of the acquisition, the director owned 2,441,379 shares of the company’s stock, valued at $70,799,991. This trade represents a -1,870.00% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Andrew J. Mills purchased 2,586,206 shares of the stock in a transaction on Thursday, December 18th. The stock was acquired at an average price of $29.00 per share, for a total transaction of $74,999,974.00. Following the completion of the purchase, the director directly owned 2,586,206 shares in the company, valued at approximately $74,999,974. The trade was a ∞ increase in their position. The SEC filing for this purchase provides additional information.

Hedge Funds Weigh In On Medline

Several hedge funds have recently modified their holdings of MDLN. Perigon Wealth Management LLC acquired a new stake in shares of Medline in the fourth quarter valued at about $211,000. SteelPeak Wealth LLC bought a new position in Medline in the fourth quarter valued at approximately $441,000. Sound Income Strategies LLC acquired a new position in shares of Medline during the 4th quarter worth approximately $25,000. Massachusetts Financial Services Co. MA bought a new stake in shares of Medline during the 4th quarter worth approximately $429,544,000. Finally, Baillie Gifford & Co. acquired a new stake in shares of Medline in the 4th quarter valued at approximately $437,236,000.

Medline News Roundup

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Citigroup raised its price target to $60 and kept a “buy” rating — a ~26.6% upside from the recent price, highlighting conviction after the quarter. Citigroup Raise
• Positive Sentiment: UBS increased its target to $57 and maintained a “buy” rating — ~20.2% upside — reflecting upgraded forecasts post-Q4. UBS Raise
• Positive Sentiment: BMO lifted its target to $54 and set an “outperform” rating (~13.9% upside), joining other brokers in boosting estimates after the quarter. BMO Raise
• Positive Sentiment: RBC raised its target to $53 with an “outperform” call (~11.8% upside), another vote of confidence from the street. RBC Raise
• Neutral Sentiment: Analysts broadly boosted forecasts after Q4 results; summary coverage aggregates the upgrades and modeling adjustments. Analysts Boost Forecasts
• Neutral Sentiment: Medline’s Q4 earnings call highlighted record sales and strategic innovations — supportive for revenue trajectory but mixed vs. EPS expectations. Earnings Call Highlights
• Neutral Sentiment: Full earnings call transcript is available for investors who want detail on guidance, margin commentary and management tone. Earnings Transcript
• Neutral Sentiment: Wells Fargo raised its target slightly to $47 but kept an “equal weight” rating — effectively neutral near-term guidance from this shop. Wells Fargo Note
• Negative Sentiment: Shares gapped down after what coverage labels a weak earnings print (EPS miss despite a revenue beat), which prompted the initial selloff. Shares Gap Down
• Negative Sentiment: As Medline transitions to public markets, the IPO/ESOP disclosures and management’s growth guidance drew public scrutiny — a source of near-term uncertainty for investors. IPO Scrutiny

About Medline

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.